GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (OTCPK:SZLSF) » Definitions » E10

SZLSF (StageZero Life Sciences) E10 : $-0.52 (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is StageZero Life Sciences E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

StageZero Life Sciences's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.003. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.52 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was 20.50% per year. During the past 5 years, the average E10 Growth Rate was 22.10% per year. During the past 10 years, the average E10 Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of StageZero Life Sciences was 26.00% per year. The lowest was 1.40% per year. And the median was 12.55% per year.

As of today (2025-07-05), StageZero Life Sciences's current stock price is $0.0228. StageZero Life Sciences's E10 for the quarter that ended in Sep. 2024 was $-0.52. StageZero Life Sciences's Shiller PE Ratio of today is .


StageZero Life Sciences E10 Historical Data

The historical data trend for StageZero Life Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences E10 Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.85 -1.16 -1.02 -0.87 -0.67

StageZero Life Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.62 -0.52 -0.43 -0.02 -0.52

Competitive Comparison of StageZero Life Sciences's E10

For the Diagnostics & Research subindustry, StageZero Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Shiller PE Ratio falls into.


;
;

StageZero Life Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, StageZero Life Sciences's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.003/127.2847*127.2847
=-0.003

Current CPI (Sep. 2024) = 127.2847.

StageZero Life Sciences Quarterly Data

per share eps CPI Adj_EPS
201409 -0.160 99.394 -0.205
201412 -0.320 98.367 -0.414
201503 -0.160 99.789 -0.204
201506 -0.240 100.500 -0.304
201509 -0.320 100.421 -0.406
201512 -0.160 99.947 -0.204
201603 -0.400 101.054 -0.504
201606 -0.160 102.002 -0.200
201609 -0.320 101.765 -0.400
201612 0.160 101.449 0.201
201703 -0.160 102.634 -0.198
201706 -0.080 103.029 -0.099
201709 -0.080 103.345 -0.099
201712 -0.026 103.345 -0.032
201803 -0.038 105.004 -0.046
201806 -0.160 105.557 -0.193
201809 -0.080 105.636 -0.096
201812 0.080 105.399 0.097
201903 -0.240 106.979 -0.286
201906 -0.026 107.690 -0.031
201909 0.080 107.611 0.095
201912 -0.017 107.769 -0.020
202003 -0.080 107.927 -0.094
202006 -0.010 108.401 -0.012
202009 -0.050 108.164 -0.059
202012 -0.025 108.559 -0.029
202103 -0.080 110.298 -0.092
202106 0.050 111.720 0.057
202109 -0.020 112.905 -0.023
202112 -0.050 113.774 -0.056
202203 -0.010 117.646 -0.011
202206 -0.010 120.806 -0.011
202209 0.000 120.648 0.000
202212 -0.090 120.964 -0.095
202303 -0.020 122.702 -0.021
202306 -0.003 124.203 -0.003
202309 -0.010 125.230 -0.010
202403 -0.003 126.258 -0.003
202406 -0.005 127.522 -0.005
202409 -0.003 127.285 -0.003

Add all the adjusted EPS together and divide 10 will get our e10.


StageZero Life Sciences  (OTCPK:SZLSF) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


StageZero Life Sciences E10 Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.